Lobaplatin Combined Floxuridine/Pirarubicin-based Transcatheter Hepatic Arterial Chemoembolization for Unresectable Primary Hepatocellular Carcinoma

Zhao, Chang; Wang, Xu-Jie; Wang, Song; Feng, Wei-Hua; Shi, Lei; Yu, Chun-Peng

추천

검색

자료유형: 학술저널

저자정보: Zhao, Chang (Department of Interventional Therapy, Affiliated Tumor Hospital of Guangxi Medical University) Wang, Xu-Jie (The Affiliated Hospital of Qingdao University) Wang, Song (The Affiliated Hospital of Qingdao University) Feng, Wei-Hua (The Affiliated Hospital of Qingdao University) Shi, Lei (The Affiliated Hospital of Qingdao University) Yu, Chun-Peng (The Affiliated Hospital of Qingdao University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제5호

발행연도: 2014.1

수록면: 2,057 - 2,060 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: To assess the effect and safety of lobaplatin combinated floxuridine /pirarubicin in transcatheter hepatic arterial chemoembolization(TACE) of unresectable primary liver cancer. Patients and Methods: TACE combined with the chemotherapy regimen was used to treat 34 unresectable primary liver cancer patients. DSA/MRI/CT/blood routine examinations were used to evaluate short term activity and toxicity after 4-5 weeks, the process being repeated if necessary. Results: Among the 34 cases, 1 (2.9%) showed a complete response, 21 (61.7%) a partial response, 8 (23.5%) stable disease, and 4 progressive disease, with a total effective rate of 67.6%. The content of alpha fetoprotein dropped by over 50% in 20 cases (58.8%). The rate of recovery was hepatalgia (88.2%), ascites (47.1%), appetite (55.9%), Performance Status(30.4%). The median follow-up time (MFT) was 281 days (63-558 days), and median progression-free survival was 118.5 days (95%, CI:88.8-148.2days). Adverse reactions (III-IV grade) were not common, with only 4 cases of vomiting and 2 cases of thrombocytopenia (III grade). Conclusions: Lobaplatin-based TACE is an effective and safe treatment for primary liver cancer.

#Primary hepatic carcinoma #chemoembolization #platinum chemotherapy #clinical response

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

이 논문의 저자 정보

Zhao, Chang

소속기관 Department of Interventional Therapy, Affiliated Tumor Hospital of Guangxi Medical University